Who
Steven D. Rubin
Director
Company insider
Files Form 4 as: Director, Entera Bio; Executive VP-Administration, Opko Health; Director, Niagen Bioscience; Director, Eloxx Pharmaceuticals; Director, Red Violet; Director, Cocrystal Pharma; Director, Castle Brands; Director, VBI Vaccines Inc/BC.
In numbers
- Trades disclosed
- 240
- Buys
- 27
- Sells
- 3
- Bought
- $580K
- Sold
- $1.9M
- Companies
- 15
- Companies where not an officer
- 12
- First trade
- 27 Mar 2007
- Last trade
- 7 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —19,117 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —33,368 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —43,405 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —33,368 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —43,405 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Code A | —19,117 at $0.00 | filing |
| 24 Jul 2026filed 28 Jul 2026 | OPK Opko HealthBiotechnology | SEC FORM 4 Code F | $65K53,266 at $1.22 | filing |
| 24 Jul 2026filed 28 Jul 2026 | OPK Opko HealthBiotechnology | SEC FORM 4 Code F | $65K53,266 at $1.22 | filing |
| 24 Jun 2026filed 26 Jun 2026 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —31,746 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | NAGE Niagen Bioscienceoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —31,746 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | ELOX Eloxx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,018 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | ELOX Eloxx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,018 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | RDVT Red VioletSoftware | SEC FORM 4 Code A | —2,179 | filing |
| 4 Jun 2026filed 5 Jun 2026 | RDVT Red VioletSoftware | SEC FORM 4 Code A | —2,179 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $7,4505,000 at $1.49 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $7,4505,000 at $1.49 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $12K10,000 at $1.20 | filing |
| 9 Feb 2026filed 11 Feb 2026 | ENTX Entera BioBiotechnology | SEC FORM 4 Bought | $12K10,000 at $1.20 | filing |
| 24 Jan 2026filed 8 May 2026 | ELOX Eloxx PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —1,875 | filing |
| 24 Jan 2026filed 8 May 2026 | ELOX Eloxx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,875 at $0.00 | filing |
News
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual MeetingENTX · manilatimes.net · 8 Oct 2026
0 headlines in the last 90 days name Steven D. Rubin; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.